 NEWTON, Mass., Dec. 18, 2020 PRNewswire -- Karyopharm Therapeutics Inc. Nasdaq: KPTI, a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the U.S. Food and Drug Administration FDA has approved XPOVIO selinexor, the Companys... 